Disability is the major negative predictor for achievement of Boolean-based remission in patients with rheumatoid arthritis treated with tocilizumab

References

• Pinals RS, Masi AT, Larsen RA. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum. 1981; 24: 1308–1315.
   PubMed Web of Science ®Google Scholar
• Prevoo ML, Gestel AM, T Hof MA, et al. Remission in a prospective study of patients with rheumatoid arthritis. American rheumatism association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol. 1996; 35: 1101–1105.
   PubMedGoogle Scholar
• Prevoo ML, van ‘t Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995; 38: 44–48.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003; 42: 244–257.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005; 7: R796–R806.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Ward MM, Machold KP, et al. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum. 2005; 52: 2625–2636.
   PubMed Web of Science ®Google Scholar
• Rezaei H, Saevarsdottir S, Forslind K, et al. In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial. Ann Rheum Dis. 2012; 71: 186–191.
   PubMedGoogle Scholar
• Felson DT, Smolen JS, Wells G, et al. American college of rheumatology/European league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011; 70: 404–413.
   PubMed Web of Science ®Google Scholar
• Nishimoto N. Interleukin-6 in rheumatoid arthritis. Curr Opin Rheumatol. 2006; 18: 277–281.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004; 50: 1761–1769.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009; 19: 12–19.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008; 371: 987–997.
   PubMed Web of Science ®Google Scholar
• Iking-Konert C, Aringer M, Wollenhaupt J, et al. Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria. Ann Rheum Dis. 2011; 70: 1986–1990.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Tanaka Y, Inoue E, et al. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Mod Rheumatol. 2011; 21: 122–133.
   PubMed Web of Science ®Google Scholar
• Kawashiri SY, Kawakami A, Iwamoto N, et al. Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index. Mod Rheumatol. 2011; 21: 365–369.
   PubMed Web of Science ®Google Scholar
• Yoshida K, Tokuda Y, Oshikawa H, et al. An observational study of tocilizumab and TNF-alpha inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safety. Rheumatology (Oxford). 2011; 50: 2093–2099.
   PubMedGoogle Scholar
• Yabe Y, Kojima T, Kaneko A, et al. A review of tocilizumab treatment in 122 rheumatoid arthritis patients included in the Tsurumai biologics communication registry (TBCR) study. Mod Rheumatol. 2012.
   Google Scholar
• Kojima T, Kaneko A, Hirano Y, et al. Early aggressive intervention with tocilizumab for rheumatoid arthritis increases remission rate defined using a Boolean approach in clinical practice. Mod Rheumatol. 2012; 22: 370–375.
   PubMed Web of Science ®Google Scholar
• Matsuda Y, Singh G, Yamanaka H, et al. Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheumatoid arthritis. Arthritis Rheum. 2003; 49: 784–788.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Takagi N. Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI study. Mod Rheumatol. 2010; 20: 539–547.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum. 2011; 63: 43–52.
   PubMed Web of Science ®Google Scholar
• Shaver TS, Anderson JD, Weidensaul DN, et al. The problem of rheumatoid arthritis disease activity and remission in clinical practice. J Rheumatol. 2008; 35: 1015–1022.
   PubMed Web of Science ®Google Scholar
• Sokka T, Hetland ML, Makinen H, et al. Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. Arthritis Rheum. 2008; 58: 2642–2651.
   PubMed Web of Science ®Google Scholar
• Klarenbeek NB, Koevoets R, Heijde DM, et al. Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis. Ann Rheum Dis. 2011; 70: 1815–1821.
   PubMed Web of Science ®Google Scholar
• Wechalekar MD, Lester S, Proudman SM, et al. Active foot synovitis in patients with rheumatoid arthritis: applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement. Arthritis Rheum. 2012; 64: 1316–1322.
   PubMed Web of Science ®Google Scholar
• Eurenius E, Brodin N, Lindblad S, et al. Predicting physical activity and general health perception among patients with rheumatoid arthritis. J Rheumatol. 2007; 34: 10–15.
   PubMed Web of Science ®Google Scholar
• Wells GA, Tugwell P, Kraag GR, et al. Minimum important difference between patients with rheumatoid arthritis: the patient’s perspective. J Rheumatol. 1993; 20: 557–560.
   PubMed Web of Science ®Google Scholar
• Pope JE, Khanna D, Norrie D, et al. The minimally important difference for the health assessment questionnaire in rheumatoid arthritis clinical practice is smaller than in randomized controlled trials. J Rheumatol. 2009; 36: 254–259.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum. 2006; 54: 2784–2792.
   PubMed Web of Science ®Google Scholar